Literature DB >> 26380334

Fever and Cardiac Arrest in a Patient With a Left Ventricular Assist Device.

Eugene M Tan1, Jasmine R Marcelin1, Aaron J Tande1, Stacey A Rizza1, Nathan W Cummins1.   

Abstract

A 68-year-old avid deer hunter with ischemic cardiomyopathy underwent left ventricular assist device (LVAD) implantation for destination therapy two years ago. He was living an active lifestyle, tracking deer and fishing in a Midwestern forest in November. His wife removed an engorged tick on his thorax. A few days later, he experienced fever, confusion, and ataxia and was hospitalized with septic shock and ventricular fibrillation. The LVAD site had no signs of trauma, drainage, warmth, or tenderness. A peripheral blood smear revealed intraleukocytic anaplasma microcolony inclusions. After completing 14 days of doxycycline, he recovered. Typical non-device-associated infections in LVAD recipients include pneumonia, urinary tract infection, or Clostridium difficile colitis. Human granulocytic anaplasmosis (HGA) is a very atypical non-LVAD infection, and the incidence of tickborne illnesses in LVAD recipients is unknown.

Entities:  

Keywords:  Anaplasma; fever; left ventricular assist device

Year:  2015        PMID: 26380334      PMCID: PMC4567092          DOI: 10.1093/ofid/ofv033

Source DB:  PubMed          Journal:  Open Forum Infect Dis        ISSN: 2328-8957            Impact factor:   3.835


A 68-year-old avid deer hunter with ischemic cardiomyopathy underwent left ventricular assist device (LVAD) implantation for destination therapy 2 years ago. Recently, he experienced several days of fever, malaise, anorexia, ataxia, and confusion. Just 2 weeks prior, he was living an active lifestyle, tracking deer and fishing in a Midwestern forest in November. His wife removed an engorged tick on his thorax. He presented in septic shock and ventricular fibrillation. The LVAD site had no signs of trauma, drainage, warmth, or tenderness. Evaluation revealed a white blood cell count of 6.3 × 109/L with 96% polymorphonuclear leukocytes and 1% lymphocytes, platelets 23 × 109/L, creatinine 3.1 mg/dL, aspartate aminotransferase 216 U/L, and total bilirubin 1.4 mg/dL. He was empirically treated with vancomycin, ceftriaxone, ampicillin, doxycycline, and metronidazole. Blood cultures were negative, but a peripheral blood smear (Figures 1 and 2) revealed intraleukocytic anaplasma microcolony inclusions (morulae), with 30% parasitemia. Polymerase chain reaction on peripheral blood was positive for Anaplasma phagocytophilum and negative for Borrelia burgdorferi and Babesia microti.
Figure 1.

Peripheral blood smear (Wright-Giemsa stain, 10× original magnification).

Figure 2.

Peripheral blood smear (Wright-Giemsa stain, 40× original magnification) demonstrating intracytoplasmic anaplasma microcolony inclusions (morulae) within leukocytes (arrowhead and inset).

Peripheral blood smear (Wright-Giemsa stain, 10× original magnification). Peripheral blood smear (Wright-Giemsa stain, 40× original magnification) demonstrating intracytoplasmic anaplasma microcolony inclusions (morulae) within leukocytes (arrowhead and inset). He completed 14 days of doxycycline. His home warfarin therapy was adjusted for drug interactions. His hospital course was complicated by acute kidney injury, disseminated intravascular coagulation, aspiration pneumonia, and recurrent ventricular fibrillation necessitating implantable cardioverter defibrillator placement. However, he recovered and was dismissed on hospital day 31. He continues to do well 3 years later. Human granulocytic anaplasmosis is a tick-borne infection that should be suspected when patients from endemic regions present with fever (85%), leukopenia, and thrombocytopenia (83%) [1]. The bacterium A phagocytophilum is transmitted by the Ixodes scapularis tick, which also transmits B burgdorferi and B microti. Human granulocytic anaplasmosis can be fatal; therefore, clinical suspicion necessitates empiric doxycycline until diagnostic confirmation [2]. Left ventricular assist device recipients typically present with poor functional capacity and device-associated infections involving the pump, cannula, pocket, driveline, or bloodstream [3]. However, in the destination therapy era, patients are living longer and can present with nondevice infections [4, 5]. The 2009 HeartMate II destination therapy trial demonstrated a 49% rate of non-LVAD infections [6]. In a 2010 study on 81 LVAD recipients, non-LVAD infections included pneumonia (8.6%), urinary tract infection (12.3%), and Clostridium difficile colitis (8.6%) [7]. Catheter-related bloodstream infections due to coagulase-negative staphylococci (40%) and Staphylococcus aureus (20%) are also common [8]. Our patient was infected with A phagocytophilum, which is a very atypical non-LVAD associated infection. The epidemiology of tick-borne illnesses in LVAD recipients is unknown.
  8 in total

1.  Nosocomial infections in left ventricular assist device recipients.

Authors:  Preeti N Malani; David B S Dyke; Francis D Pagani; Carol E Chenoweth
Journal:  Clin Infect Dis       Date:  2002-04-22       Impact factor: 9.079

2.  Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts.

Authors:  Ana A Weil; Elinor L Baron; Catherine M Brown; Mark S Drapkin
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

3.  Infectious complications in patients with left ventricular assist device: etiology and outcomes in the continuous-flow era.

Authors:  Veli K Topkara; Sreekanth Kondareddy; Fardina Malik; I-Wen Wang; Douglas L Mann; Gregory A Ewald; Nader Moazami
Journal:  Ann Thorac Surg       Date:  2010-10       Impact factor: 4.330

4.  Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation.

Authors:  Justin M Schaffer; Jeremiah G Allen; Eric S Weiss; George J Arnaoutakis; Nishant D Patel; Stuart D Russell; Ashish S Shah; John V Conte
Journal:  J Heart Lung Transplant       Date:  2011-02       Impact factor: 10.247

5.  Advanced heart failure treated with continuous-flow left ventricular assist device.

Authors:  Mark S Slaughter; Joseph G Rogers; Carmelo A Milano; Stuart D Russell; John V Conte; David Feldman; Benjamin Sun; Antone J Tatooles; Reynolds M Delgado; James W Long; Thomas C Wozniak; Waqas Ghumman; David J Farrar; O Howard Frazier
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

Review 6.  Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment.

Authors:  J Stephen Dumler; John E Madigan; Nicola Pusterla; Johan S Bakken
Journal:  Clin Infect Dis       Date:  2007-07-15       Impact factor: 9.079

7.  Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.

Authors:  Katherine Lietz; James W Long; Abdallah G Kfoury; Mark S Slaughter; Marc A Silver; Carmelo A Milano; Joseph G Rogers; Yoshifumi Naka; Donna Mancini; Leslie W Miller
Journal:  Circulation       Date:  2007-07-16       Impact factor: 29.690

8.  Clinical manifestations and management of left ventricular assist device-associated infections.

Authors:  Juhsien Jodi C Nienaber; Shimon Kusne; Talha Riaz; Randall C Walker; Larry M Baddour; Alan J Wright; Soon J Park; Holenarasipur R Vikram; Michael R Keating; Francisco A Arabia; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.